151 related articles for article (PubMed ID: 37468228)
21. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.
Laine L; Hunt R; El-Zimaity H; Nguyen B; Osato M; Spénard J
Am J Gastroenterol; 2003 Mar; 98(3):562-7. PubMed ID: 12650788
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness of empirical
Bordin DS; Voynovan IN; Sarsenbaeva AS; Zaytsev OV; Abdulkhakov RA; Bakulina NV; Bakulin IG; Osipenko MF; Livzan MA; Alekseenko SA; Tarasova LV; Tarasova GN; Bogomolov PO; Maev IV; Andreev DN; Abdulkhakov SR; Starostin BD; Bakanova NV; Kononova AG; Kolbasnikov SV; Bueverova EL; Moreira L; Megraud F; O'Morain C; Perez Nyssen O; Gisbert J
Ter Arkh; 2023 Mar; 95(2):120-129. PubMed ID: 37167127
[TBL] [Abstract][Full Text] [Related]
23. European Registry on
Caldas M; Pérez-Aisa Á; Castro-Fernández M; Bujanda L; Lucendo AJ; Rodrigo L; Huguet JM; Pérez-Lasala J; Molina-Infante J; Barrio J; Fernández-Salazar L; Lanas Á; Perona M; Domínguez-Cajal M; Ortuño J; Gómez-Rodríguez BJ; Almela P; Botargués JM; Núñez Ó; Modolell I; Gómez J; Ruiz-Zorrilla R; De la Coba C; Huerta A; Iyo E; Pozzati L; Antón R; Barenys M; Angueira T; Fernández-Bermejo M; Campillo A; Alcedo J; Pajares-Villaroya R; Mego M; Bermejo F; Dominguez-Jiménez JL; Titó L; Fernández N; Pabón-Carrasco M; Cosme Á; Mata-Romero P; Alcaide N; Ariño I; Di Maira T; Garre A; Puig I; Nyssen OP; Megraud F; O'Morain C; Gisbert JP;
Antibiotics (Basel); 2020 Dec; 10(1):. PubMed ID: 33375717
[TBL] [Abstract][Full Text] [Related]
24. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Poonyam P; Chotivitayatarakorn P; Vilaichone RK
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
[TBL] [Abstract][Full Text] [Related]
25. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
Nyssen OP; Perez-Aisa A; Tepes B; Castro-Fernandez M; Kupcinskas J; Jonaitis L; Bujanda L; Lucendo A; Jurecic NB; Perez-Lasala J; Shvets O; Fadeenko G; Huguet JM; Kikec Z; Bordin D; Voynovan I; Leja M; Machado JC; Areia M; Fernandez-Salazar L; Rodrigo L; Alekseenko S; Barrio J; Ortuño J; Perona M; Vologzhanina L; Romero PM; Zaytsev O; Rokkas T; Georgopoulos S; Pellicano R; Buzas GM; Modolell I; Gomez Rodriguez BJ; Simsek I; Simsek C; Lafuente MR; Ilchishina T; Camarero JG; Dominguez-Cajal M; Ntouli V; Dekhnich NN; Phull P; Nuñez O; Lerang F; Venerito M; Heluwaert F; Tonkic A; Caldas M; Puig I; Megraud F; O'Morain C; Gisbert JP;
Am J Gastroenterol; 2021 Jun; 116(6):1220-1229. PubMed ID: 33840725
[TBL] [Abstract][Full Text] [Related]
26. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
28. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
Rodríguez de Santiago E; Martín de Argila de Prados C; Marcos Prieto HM; Jorge Turrión MÃ; Barreiro Alonso E; Flores de Miguel A; de la Coba Ortiz C; Rodríguez Escaja C; Pérez Álvarez G; Ferre Aracil C; Aguilera Castro L; García García de Paredes A; Rodríguez Pérez A; Albillos Martínez A
Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28771880
[TBL] [Abstract][Full Text] [Related]
29. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
Nyssen OP; McNicholl AG; Gisbert JP
Helicobacter; 2019 Apr; 24(2):e12570. PubMed ID: 30767339
[TBL] [Abstract][Full Text] [Related]
31. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease].
Veliev AM; Maev IV; Andreev DN; Dicheva DT; Zaborovskii AV; Lobanova EG; Bektemirova LG
Ter Arkh; 2019 Aug; 91(8):28-33. PubMed ID: 32598751
[TBL] [Abstract][Full Text] [Related]
32. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
33. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
34. Empirical rescue treatment of
Burgos-Santamaría D; Nyssen OP; Gasbarrini A; Vaira D; Pérez-Aisa Á; Rodrigo L; Pellicano R; Keco-Huerga A; Pabón-Carrasco M; Castro-Fernandez M; Boltin D; Barrio J; Phull P; Kupcinskas J; Jonaitis L; Ortiz-Polo I; Tepes B; Lucendo AJ; Huguet JM; Areia M; Jurecic NB; Denkovski M; Bujanda L; Ramos-San Román J; Cuadrado-Lavín A; Gomez-Camarero J; Jiménez Moreno MA; Lanas A; Martinez-Dominguez SJ; Alfaro E; Marcos-Pinto R; Milivojevic V; Rokkas T; Leja M; Smith S; Tonkić A; Buzás GM; Doulberis M; Venerito M; Lerang F; Bordin DS; Lamy V; Capelle LG; Marlicz W; Dobru D; Gridnyev O; Puig I; Mégraud F; O'Morain C; Gisbert JP;
Gut; 2022 Dec; ():. PubMed ID: 36591610
[TBL] [Abstract][Full Text] [Related]
35. Impact of insufficient doses of medications on
Shi X; Wang C; Meng F; Ma S; Xu G; Liu T; Guo X; Li H; Qi X
Postgrad Med; 2022 Sep; 134(7):668-674. PubMed ID: 35860966
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
37. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
38. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Choe JW; Jung SW; Kim SY; Hyun JJ; Jung YK; Koo JS; Yim HJ; Lee SW
Helicobacter; 2018 Apr; 23(2):e12466. PubMed ID: 29369454
[TBL] [Abstract][Full Text] [Related]
40. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
